Provera improves condition of women whose menstrual periods have stopped or in case of an abnormal bleeding of uterus due to hormone imbalance.
Active substance of Provera
Excipients: corn starch; magnesium stearate; MCC; gelatin; polyethylene glycol 400; sodium starch glycolate; sodium docusate (85%) sodium benzoate (15%)
Pharmacological groups of Provera
Estrogens, progestins; antagonists, and their homologs
Antineoplastic hormonal and hormone antagonists
The nosological classification (ICD-10)
C50 Malignant neoplasm of breast
C54.1 Malignant neoplasm of the endometrium
C64 Malignant neoplasm of kidney, except renal pelvis
The drug forms of Provera
Tablets 100 mg: white, round, flat scored.
Tablets 500 mg: white, oblong, biconvex.
Indications for use Provera
Hormone-dependent breast cancer forms in postmenopausal women recurrent cancer (palliative treatment), recurrent and / or metastatic cancer of the endometrium, kidney (additional and / or palliative treatment).
Contraindications of Provera
From the nervous system and sensory organs: dizziness, headache, nervousness, sleep disorders, drowsiness, weakness, depression.
Cardio-vascular system and blood (blood, hemostasis): thrombosis, thrombophlebitis.
Allergic reactions: rash, urticaria; in some cases — anaphylactoid reactions.
Other: nausea, breast tenderness, galactorrhea, increased body temperature, Cushing’s syndrome (chronic administration of high doses).
Dosing and Administration
Inside, in recurrent breast cancer in postmenopausal women at 400-1200 mg / day in patients with recurrent endometrial cancer and kidney — at 200-600 mg / day.
For use in oncology: additional and palliative treatment of recurrent and metastatic endometrial cancer or kidney cancer; palliative treatment of hormone-dependent forms of breast cancer in women of recurrent cancer in post-menopausal; prostate carcinoma, certain forms of BPH; cancer cachexia in advanced tumors of various localization.